Healthcare Industry News: CereTom
News Release - June 4, 2008
Korean FDA Approves the CereTom(R) Portable CT Scanner
DANVERS, Mass. & SEOUL, Korea--(HSMN NewsFeed)--NeuroLogica Corporation and its Korean distribution partner, Dong Kang Medical Systems Co.,Ltd., announced that the CereTom(R) has received clearance from the Korean Food and Drug Administration (KFDA) for medical capital device imaging.“We are thrilled that the CereTom has cleared Korean FDA,” said Eric M. Bailey, CEO and President of NeuroLogica Corporation. “South Korea is one of the most innovative and medically advanced countries in Asia, we are confident that the CereTom will improve the standard of care for critically ill patients with neurological emergencies. Our distribution partner, Dong Kang, Co. has an excellent reputation at the best medical institutions in South Korea. We are pleased that they will be representing the CereTom.”
“The CereTom is an excellent addition to our product portfolio,” says Mrs. Shim President of Dong Kang, Co. “With the innovation and flexibility of the CereTom, Korean hospitals can now benefit with scanning critical care patients in an efficient manner while eliminating the need to transport. This is the reason why the CereTom will be such a success in Korea.”
The CereTom is a portable eight slice CT scanner that acquires 1.25mm slices per rotation. It is capable of performing NeCT, CT Perfusion, Xenon Perfusion and CT Angiography. It is also optimal for use in the emergency room, intensive care unit and operating room because of its portability and ease of use. The CereTom is installed in over 100 of the top medical centers world wide.
About NeuroLogica
NeuroLogica Corporation, located in Danvers, Massachusetts, develops, manufactures and markets innovative medical imaging equipment for healthcare facilities world wide. The company’s mission is to bring high quality medical imaging to all people regardless of where they live. For more information about NeuroLogica please visit their website at www.neurologica.com.
Source: NeuroLogica Corp
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
